Postponed clinical trials affect ALK finances – central phase III trials have been delayed

The Monday guidance upgrade from allergy company ALK, which was confirmed on Wednesday morning, especially happened because sales had been better than expected, but also due to a series of savings and necessary postponements of clinical trials, such as the crucial Chinese phase III trial, which was meant to start in August, explains CEO Carsten Hellmann.

ALK CEO Carsten Hellmann | Photo: Gregers Tycho/Ritzau/Ritzau Scanpix

Monday afternoon, Danish allergy company ALK upgraded the guidance for its main figures relating to revenue and earnings ahead of today's presentation of the firm's quarterly report.

This is mainly because sales have gone better than expected, but also due to savings on certain expenses and necessary postponements of clinical trials. Because of these factors, ALK foresees better operating results than previously announced.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs